Highlights Newsletter 1

This newsletter presents you the following key sessions:

1. Podcast with dr. Kai Keen Shiu about the phase III randomized study of pembrolizumab versus
    chemotherapy for patients with microsatellite-instability-high advanced colorectal cancer

2. Adjuvant S-1 plus docetaxel superior to S-1 monotherapy after a curative resection of stage III
    gastric cancer

3. Impact of neoadjuvant therapies on the risk for perioperative complications in patients with
    advanced thoracic oesophageal cancer

4. Trifluridine/tipiracil provides the greatest clinical benefit when used in the third line treatment
    of patients with metastatic gastric cancer

5. The FGFR-selective tyrosine kinase inhibitor infigratinib shows promising efficacy in patients
    advanced cholangiocarcinoma harbouring FGFR2 alterations